Vertex Executive and Leadership Team

Md Reshma Kewalramani, the Chief Executive Officer & President at Vertex, directs the company's overarching strategy and operational execution. This leadership role involves guiding Vertex's mission to develop and commercialize medicines for serious diseases with significant unmet medical needs, including therapies for cystic fibrosis, sickle cell disease, and transfusion-dependent beta thalassemia. Kewalramani oversees the advancement of research programs in areas such as kidney disease, type 1 diabetes, and myotonic dystrophy, ensuring a robust pipeline of innovative treatments. The Chief Executive Officer & President drives the company's global expansion and market presence, coordinating efforts across research, development, and commercialization to reach patients worldwide. This executive ensures alignment with Vertex's core values and commitment to scientific excellence, positioning the company at the forefront of biotechnology innovation. Md Reshma Kewalramani's strategic vision shapes the company's direction, fostering a culture of discovery and patient-centricity to address critical health challenges.

Stephanie Franklin, the Senior VP & Chief Human Resources Officer at Vertex, architects the human capital strategy essential for Vertex's scientific and commercial objectives. This leadership position involves cultivating a high-performance culture that attracts, develops, and retains top talent across all functional areas, from cutting-edge research to global commercial operations. Franklin oversees the comprehensive human resources infrastructure, ensuring robust talent management, competitive compensation and benefits, and effective employee engagement programs that support the company's mission. The Senior VP & Chief Human Resources Officer plays a critical part in aligning organizational structure and workforce planning with Vertex's strategic goals, particularly in advancing therapies for serious diseases like cystic fibrosis and sickle cell disease. Stephanie Franklin's expertise ensures that Vertex's most valuable asset—its people—are empowered to drive innovation and deliver life-changing medicines to patients worldwide. This role is pivotal in fostering an inclusive and dynamic work environment conducive to groundbreaking scientific discovery and sustained business growth.

Olivia Green, the Director, Chief of Staff, U. S. Commercial at Vertex, provides strategic support and operational coordination for the U.S. commercial division. This role involves streamlining communication and execution across various commercial functions, ensuring alignment with Vertex's objectives for bringing innovative medicines to patients in the United States. Green facilitates key initiatives, manages cross-functional projects, and supports the leadership team in driving market access and commercial success for therapies targeting serious diseases. The Director, Chief of Staff, U. S. Commercial enhances operational efficiency and strategic focus within the U.S. market, contributing directly to the company's ability to serve patients with unmet medical needs. Olivia Green's efforts are crucial in optimizing the deployment of commercial resources and ensuring seamless execution of go-to-market strategies for Vertex's portfolio, including treatments for cystic fibrosis and sickle cell disease.

Rashmi Sarnaik, the Director, Chief of Staff To the Head of Medical Affairs at Vertex, enhances the strategic execution and operational effectiveness of the Medical Affairs department. This position involves coordinating critical initiatives, managing cross-functional projects, and ensuring seamless communication between the Head of Medical Affairs and various internal and external stakeholders. Sarnaik supports the strategic direction of medical affairs activities, which are vital for advancing Vertex's mission of developing medicines for serious diseases. The Director, Chief of Staff To the Head of Medical Affairs facilitates the implementation of medical strategies, including research programs and patient support initiatives, ensuring alignment with Vertex's overall corporate goals. Rashmi Sarnaik's role is instrumental in optimizing the impact of Medical Affairs, driving forward the company's commitment to scientific leadership and patient well-being across its therapeutic areas.

Colleen O'Brien, the Toxicology Research Senior Scientist & Chief Revenue Officer, Study Monitor at Vertex, brings a dual focus to scientific integrity and revenue oversight within research programs. This unique position involves ensuring the rigorous scientific validity and ethical conduct of toxicology studies, critical for the development of new medicines for serious diseases. Simultaneously, O'Brien monitors revenue-generating activities associated with study execution, ensuring financial accountability and strategic alignment. The Toxicology Research Senior Scientist & Chief Revenue Officer, Study Monitor contributes to Vertex's pipeline advancement by upholding the highest standards in preclinical research and financial management. Colleen O'Brien's expertise supports the company's commitment to developing transformative therapies, such as those for cystic fibrosis and sickle cell disease, by safeguarding both scientific quality and fiscal responsibility in research operations.

Katie Noon, the Chief of Staff & Director at Vertex, provides comprehensive strategic and operational leadership support across key organizational functions. This role involves driving critical initiatives, facilitating cross-functional collaboration, and ensuring efficient execution of Vertex's mission to develop medicines for serious diseases. Noon works closely with senior leadership to enhance strategic planning, project management, and operational effectiveness, contributing to the advancement of therapies for conditions such as cystic fibrosis and sickle cell disease. The Chief of Staff & Director plays a pivotal part in translating strategic objectives into actionable plans, optimizing resource allocation, and ensuring seamless communication throughout the organization. Katie Noon's contributions are essential in maintaining momentum for Vertex's research and development programs, reinforcing the company's commitment to addressing significant unmet medical needs globally.

Moira Scanlon, the Director, Chief of Staff - Global Commercial Strategy at Vertex, drives the strategic planning and execution of commercial initiatives on a worldwide scale. This leadership role focuses on aligning global commercial efforts with Vertex's overarching mission to deliver transformative medicines for serious diseases. Scanlon facilitates cross-functional collaboration among regional commercial teams, marketing, and sales, ensuring cohesive strategy implementation. The Director, Chief of Staff - Global Commercial Strategy enhances operational efficiency and strategic focus across international markets, supporting the successful launch and sustained growth of Vertex's therapeutic portfolio. Moira Scanlon's expertise is critical in navigating complex global healthcare landscapes and ensuring that Vertex's innovative treatments reach patients in need across diverse geographies, reinforcing the company's commitment to global health impact.

Adila Crimi, the Head To of Cell & Gene Therapy Research Chief of Staff at Vertex, provides critical strategic and operational support to the leadership of cell and gene therapy research. This role is central to advancing Vertex's pioneering work in developing novel treatments for genetic disorders. Crimi facilitates the coordination of research projects, manages key stakeholder communications, and ensures the efficient progression of scientific discovery within this cutting-edge therapeutic area. The Head To of Cell & Gene Therapy Research Chief of Staff plays a vital part in translating research breakthroughs into potential patient therapies, aligning efforts with Vertex's broader commitment to addressing serious diseases. Adila Crimi's support is essential for accelerating innovation in cell and gene therapy, reinforcing Vertex's position at the forefront of biotechnology research and development.

Sazzad Hussain, the Senior Principal Scientist and Chief Revenue Officer Monitor and Associate Director at Vertex, combines deep scientific expertise with financial oversight in research and development. This multifaceted role involves leading scientific investigations as a Senior Principal Scientist, contributing to the discovery of new medicines for serious diseases, while also serving as a Chief Revenue Officer Monitor and Associate Director to ensure financial viability and strategic resource allocation. Hussain's responsibilities encompass driving scientific innovation and managing the financial aspects of research projects, ensuring alignment with Vertex's mission. The Senior Principal Scientist and Chief Revenue Officer Monitor and Associate Director plays a crucial part in advancing Vertex's pipeline, particularly in areas like kidney disease and type 1 diabetes. Sazzad Hussain's dual focus ensures that scientific progress is both groundbreaking and fiscally responsible, supporting the company's long-term growth and patient impact.

Tatum Murray, the Senior Director, Chief of Staff To the Chief Patient and External Affairs Officer at Vertex, enhances the strategic impact and operational efficiency of patient advocacy and external relations. This role involves coordinating initiatives that strengthen Vertex's engagement with patient communities and external stakeholders, crucial for advancing therapies for serious diseases. Murray facilitates communication, manages key projects, and supports the Chief Patient and External Affairs Officer in shaping the company's external narrative and patient-centric strategies. The Senior Director, Chief of Staff To the Chief Patient and External Affairs Officer plays a vital part in ensuring that Vertex's efforts are aligned with patient needs and societal expectations. Tatum Murray's contributions are essential in fostering strong relationships and driving Vertex's commitment to making a meaningful difference in the lives of patients worldwide.